First, although our study was designed to allow the enrollment of patients with ALK-driven advanced tumors other than NSCLC, only one patient with advanced neuroblastoma, who had a commonly detected ALK F1174L mutation [19–21] and who progressed on prior crizotinib, was identified during the enrollment period. Here, ALK is linked to neuroblastoma.